

Astellas Presentations at 2025 ASCO Annual Meeting

Enzalutamide

Presentation Title	Lead Author	Presentation Details
ARCHES 5-year follow-up overall survival analysis of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer	A. Armstrong	Type: Oral Presentation Abstract Number: 5005 Date: June 3, 2025, 9:45am – 12:45pm CDT
Cardiovascular event risk in patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate in the United States	A. Bryce	Type: Poster Presentation Abstract Number: 5041 Date: June 2, 2025, 9:00am – 12:00pm CDT
Secondary outcomes by prior definitive treatment in patients with high-risk biochemically recurrent prostate cancer treated with enzalutamide monotherapy: EMBARK post hoc analysis	S. Freedland	Type: Poster Presentation Abstract Number: 5103 Date: June 2, 2025, 9:00am – 12:00pm CDT
How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veteran Health Administration data	S. Freedland	Type: Poster Presentation Abstract Number: 5092 Date: June 2, 2025, 9:00am – 12:00pm CDT
Abiraterone acetate is associated with shorter overall survival than enzalutamide in patients with chemotherapy naïve metastatic castration-resistant prostate cancer: Real world data from the Flatiron electronic health records database	D. George	Type: E-Publication Only Abstract Number for Publication: e17033
Secondary outcomes by prior definitive treatment in patients with high-risk biochemically recurrent prostate cancer (treated with enzalutamide plus leuprolide (combo): EMBARK post hoc analysis	N. Shore	Type: E-Publication Only Abstract Number for Publication: e17127
Corticosteroid Use and Risk of Adverse Events in Patients Treated for Metastatic Hormone-Sensitive Prostate Cancer	U. Swami	Type: E-Publication Only Abstract Number for Publication: e17097

Enfortumab vedotin

Presentation Title	Lead Author	Presentation Details
--------------------	-------------	----------------------

EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma	J. Bedke	Type: Poster Presentation Abstract Number: 4571 Date: June 2, 2025, 9:00am – 12:00pm CDT
Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma	S. Gupta	Type: Oral Presentation Abstract Number: 4502 Date: June 1, 2025, 9:45am – 12:45pm CDT
Evaluation of surrogate endpoints in muscle-invasive bladder cancer: A systematic review and meta-analysis	M. Galsky	Type: Poster Presentation Abstract Number: 4580 Date: June 2, 2025, 9:00am – 12:00pm CDT
Study EV-103 Cohort H: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle-invasive bladder cancer: 3-year efficacy results	N. Mar	Type: Poster Presentation Abstract Number: 4583 Date: June 2, 2025, 9:00am – 12:00pm CDT
Recent trends in US real-world first-line treatment patterns for patients with locally advanced or metastatic urothelial carcinoma	G. Sonpavde	Type: E-Publication Only Abstract Number for Publication: e16556
Patient and clinician expert perspectives on the impactful symptoms of head and neck squamous cell carcinoma and its treatment	E. Theodorou	Type: E-Publication Only Abstract Number for Publication: e18001

Zolbetuximab

Presentation Title	Lead Author	Presentation Details
A real-world study on epidemiology, biomarker test results, clinical characteristics, and treatment patterns of unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in China	Y. Chen	Type: E-Publication Only Abstract Number for Publication: e16013

Gilteritinib

Presentation Title	Lead Author	Presentation Details
--------------------	-------------	----------------------

Real-world adherence and tolerability of FLT3 inhibitors s post-allogeneic transplant maintenance therapy in older adults with AML: A Medicare claims cohort study	V. Kennedy	Type: E-Publication Only
--	------------	---------------------------------

Pipeline

Presentation Title	Lead Author	Presentation Details
Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutation	Shiraj Sen	Type: Poster Presentation Abstract Number: TPS3178 Date: June 2, 2025, 1:30 – 4:30pm CDT